Phase I and Phase II Drug Metabolism

Phase I and Phase II drug metabolism (also termed xenobiotic biotransformation) is the coordinated biochemical enzymatic network—concentrated principally in the human liver, small intestine, kidneys, and lungs—that converts lipophilic exogenous compounds (pharmaceuticals, dietary phytochemicals, and environmental toxins) into hydrophilic, water-soluble metabolites capable of rapid elimination in urine or bile. First systematized into a two-phase paradigm by the Welsh biochemist Richard Tecwyn Williams in his classic monograph Detoxication Mechanisms (1947; 2nd edition 1959), this metabolic architecture represents the primary clearance determinant in pharmacokinetics and ADMET.

Most orally active small-molecule drugs are moderately lipophilic (Log P ≈ 1.5–4.0) so they can diffuse passively across intestinal lipid bilayers and reach intracellular targets. However, if these lipophilic molecules remained chemically unchanged after glomerular filtration in the kidneys, they would be passively reabsorbed across the lipid membranes of the distal renal tubules back into systemic blood, resulting in elimination half-lives of weeks or months. Enzymatic biotransformation solves this physiological problem in two sequential steps: Phase I functionalization reactions introduce or unmask a polar reactive handle (−OH, −NH₂, −SH, or −COOH) via oxidation, reduction, or hydrolysis, and Phase II conjugation reactions covalently attach an ionized endogenous hydrophilic cofactor (glucuronate, sulfate, glutathione, acetate, or glycine) to drop the partition coefficient (Log D_7.4 < 0) and enable active extrusion by membrane drug transporters.

Microsomal Cytochrome P450 and Flavin-Containing Monooxygenases (FMOs)

The majority of Phase I oxidative metabolism is catalyzed by the heme-thiolate monooxygenase superfamily Cytochrome P450 (CYP) anchored in the cytosolic face of the hepatic and enterocytic smooth endoplasmic reticulum (isolated experimentally as the microsomal fraction after 100,000 × g ultracentrifugation). Coupled to NADPH–Cytochrome P450 Oxidoreductase (POR) and cytochrome b₅, CYP isoforms split molecular oxygen (O₂) via a high-valent iron(IV)-oxo porphyrin π-cation radical (Compound I) to catalyze aliphatic and aromatic hydroxylation, N-, O-, and S-dealkylation, epoxidation, and oxidative deamination. Seven human isoforms—CYP3A4/5 (~50% of metabolized drugs), CYP2D6 (~20%), CYP2C9 (~12%), CYP2C19 (~8%), CYP1A2 (~4%), CYP2B6, and CYP2E1—account for over 90% of CYP-mediated drug clearance.

Complementing CYPs in the endoplasmic reticulum are the microsomal Flavin-Containing Monooxygenases (FMO1–FMO5, predominantly hepatic FMO3). Unlike CYPs, FMOs utilize a prosthetic FAD cofactor and NADPH + O₂ to pre-form a stable C4a-hydroperoxyflavin intermediate before the xenobiotic substrate binds. Any soft nucleophilic heteroatom (such as tertiary amines, nicotine, benzydamine, cimetidine, or the dietary gut metabolite trimethylamine) that accesses the active site undergoes N- or S-oxygenation without requiring substrate-induced conformational gating; consequently, FMO3 is largely refractory to clinical enzyme induction or inhibition (and genetic FMO3 loss-of-function mutations cause trimethylaminuria or "fish odor syndrome").

Non-CYP Phase I Enzymes: Epoxide Hydrolase, Esterases, and Oxidoreductases

Phase I biotransformation also encompasses several vital non-microsomal and hydrolytic enzyme families:

• Microsomal and Soluble Epoxide Hydrolases (mEH / EPHX1 and sEH / EPHX2): Catalyze the trans-addition of H₂O across electrophilic arene oxides and epoxides generated during CYP oxidation of aromatic rings (such as phenytoin, carbamazepine-10,11-epoxide, or the procarcinogen benzo[a]pyrene-7,8-epoxide) via an active-site Asp nucleophile, detoxifying them into less reactive trans-1,2-dihydrodiols.
• Carboxylesterases (CES1 and CES2) and Paraoxonases: Serine hydrolases (containing a Ser–His–Glu catalytic triad) in the endoplasmic reticulum and plasma that cleave esters, amides, and carbamates—both inactivating drugs (such as cocaine, procaine, and meperidine) and bioactivating ester prodrugs (such as enalapril, oseltamivir, and irinotecan, where hepatic CES1 prefers large acyl/small alcohol esters and intestinal CES2 prefers small acyl/large alcohol esters).
• Cytosolic & Mitochondrial Oxidoreductases: Include Zn²⁺-dependent Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH2) (oxidizing ethanol and cyclophosphamide aldehyde intermediates), molybdenum-pterin Aldehyde Oxidase (AOX1) and Xanthine Oxidase (XO) (oxidizing electron-deficient nitrogen heterocycles like 6-mercaptopurine and allopurinol), mitochondrial Monoamine Oxidases (MAO-A, MAO-B) (deaminating catecholamines and triptans), and Dihydropyrimidine Dehydrogenase (DPD / DPYD) (which reduces >80% of administered 5-fluorouracil).

Because forming a covalent bond between a drug and an endogenous polar group is thermodynamically endergonic, all Phase II transferase enzymes utilize a high-energy activated cofactor. In most pathways (except glutathione conjugation), the cofactor itself carries the high-energy bond (such as UDPGA, PAPS, acetyl-CoA, or SAM), whereas in amino acid conjugation (e.g., salicylic acid → salicyluric acid or benzoic acid → hippuric acid), the xenobiotic carboxylic acid is first activated by ATP and CoA into a xenobiotic acyl-CoA thioester before reaction with glycine or taurine.

Glucuronidation (UGTs) versus Sulfation (SULTs)

1. Glucuronidation (The High-Capacity Pathway): Accounting for ~35%–45% of all Phase II drug conjugates, the UDP-glucuronosyltransferase superfamily (19 human enzymes in the UGT1A and UGT2B subfamilies, located on the luminal side of the smooth endoplasmic reticulum) catalyzes an S_N2 nucleophilic attack by a drug's −OH, −COOH, −NH₂, or −SH group onto the C1 anomeric carbon of UDP-α-D-glucuronic acid (UDPGA). This reaction proceeds with inversion of configuration to yield a water-soluble β-D-glucuronide (carrying a carboxylate with p*K*_a ≈ 3.2 that is >99.9% ionized at pH 7.4). While most glucuronides are pharmacologically inactive, morphine-6-glucuronide (M6G) is a potent full μ-opioid agonist that accumulates in renal failure, and acyl glucuronides (formed from NSAIDs like diclofenac) can undergo intramolecular acyl migration to react covalently with serum proteins. When glucuronides are excreted into bile via canalicular MRP2, colonic bacterial β-glucuronidases can cleave the sugar and allow the parent drug to be reabsorbed (enterohepatic recirculation, extending the half-life of ethinylestradiol and mycophenolate).
2. Sulfation (The High-Affinity, Low-Capacity Pathway): Cytosolic Sulfotransferases (SULT1A1, SULT1A3, SULT2A1) transfer a sulfuryl group (−SO₃⁻) from the universal donor 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to phenols and aliphatic alcohols, generating ionized sulfate esters (p*K*_a < 1). Because cellular hepatic PAPS pools (~30–100 nmol/g liver) are depleted far more rapidly than UDPGA pools (~300–500 nmol/g liver) due to slow ATP sulfurylase/APS kinase synthesis, sulfation operates as a high-affinity (low K_m), low-capacity (low V_max) pathway, whereas glucuronidation operates as a low-affinity (high K_m), high-capacity (high V_max) pathway. At low doses, phenols are predominantly sulfated; as doses increase and PAPS saturates, metabolism shifts quantitatively toward glucuronidation.

Glutathione Conjugation, Acetylation, and Methylation

1. Glutathione Conjugation and the Mercapturic Acid Pathway: Cytosolic and microsomal Glutathione S-Transferases (GST Alpha, Mu, Pi, Theta) defend the cell against reactive electrophiles generated during Phase I oxidation. An active-site tyrosine or serine residue in GST stabilizes the thiolate anion (−S⁻) of the tripeptide reduced glutathione (GSH, γ-L-Glu-L-Cys-Gly) by lowering its thiol p*K*_a from ~8.7 in solution to ~6.2, accelerating nucleophilic attack onto epoxides, haloalkanes, and quinoneimines. Following biliary or renal efflux of the GSH conjugate, extracellular γ-glutamyltransferase (GGT) and dipeptidases cleave the glutamate and glycine residues, and hepatic/renal N-acetyltransferases acetylate the resulting cysteine conjugate into a urinary mercapturic acid (N-acetylcysteine conjugate).
2. Acetylation (NAT1/NAT2) and Methylation (TPMT/COMT): Cytosolic arylamine N-acetyltransferases (NAT1, NAT2) transfer an acetyl group from acetyl-CoA to aromatic amines and hydrazines (such as isoniazid, hydralazine, procainamide, and sulfamethoxazole) via a ping-pong Bi-Bi catalytic triad mechanism involving Cys68. Cytosolic Thiopurine S-Methyltransferase (TPMT) and Catechol-O-Methyltransferase (COMT) transfer a methyl group from S-adenosyl-L-methionine (SAM) to thiopurines (6-mercaptopurine, azathioprine) and catechols (levodopa, epinephrine). Uniquely, acetylation and methylation decrease water solubility rather than increasing it, though they terminate pharmacological or toxic reactivity.

How does the interplay between Phase I and Phase II metabolism explain acetaminophen hepatotoxicity and its treatment with N-acetylcysteine?

At therapeutic doses (≤4 g/day in healthy adults), 85%–90% of acetaminophen (paracetamol) bypasses Phase I entirely because it already possesses a phenolic −OH group, undergoing direct Phase II glucuronidation (via UGT1A1/1A6/1A9, ~55%–60%) and sulfation (via SULT1A1, ~30%). Only 5%–10% undergoes Phase I oxidation by CYP2E1 (and CYP3A4/1A2) into the reactive electrophilic quinoneimine NAPQI (N-acetyl-p-benzoquinone imine), which is immediately detoxified by GST-catalyzed conjugation with reduced glutathione (GSH) into benign mercapturic acid. In an acute overdose (>150 mg/kg or >10 g), the sulfation PAPS pool and glucuronidation capacity become saturated, shunting excessive acetaminophen through CYP2E1. Once hepatic GSH reserves fall below 30% of normal, unquenched NAPQI covalently arylates mitochondrial protein thiols, triggering centrilobular hepatic necrosis. Intravenous or oral N-acetylcysteine (NAC) rescues the liver by serving as a cysteine precursor that rapidly replenishes intracellular hepatic GSH synthesis.

Why do neonates develop "Gray Baby Syndrome" when treated with chloramphenicol, and why are patients with Gilbert syndrome sensitive to irinotecan?

Both syndromes stem from reduced activity of Phase II UDP-glucuronosyltransferase 1A1 (UGT1A1). In premature and newborn infants, hepatic UGT2B7 and UGT1A1 transcription does not reach adult levels until 3 to 6 months of age; when administered the antibiotic chloramphenicol, neonates cannot conjugate it into the water-soluble glucuronide, leading to toxic parent-drug accumulation that inhibits mitochondrial ribosomal peptidyl transferase and causes cardiovascular collapse, acidosis, and ashen-gray cyanosis (Gray Baby Syndrome). In adults with Gilbert syndrome (~10% of populations), a homozygous TA-repeat insertion in the UGT1A1 TATA box promoter (\*28 allele) reduces UGT1A1 expression by ~70%. When treated with the oncology prodrug irinotecan, *UGT1A1\*28/\*28* patients cannot efficiently glucuronidate its active topoisomerase I-inhibiting metabolite SN-38, causing severe life-threatening neutropenia and secretory diarrhea.

Why do Phase II acetylation and methylation reactions decrease water solubility instead of increasing it like glucuronidation or sulfation?

Whereas glucuronidation, sulfation, and glutathione conjugation attach large, permanently ionized carboxylate or sulfonate groups (reducing Log D_7.4 by 2 to 4 log units), acetylation (via NAT2) caps a polar, hydrogen-bond-donating primary amine (−NH₂) or hydrazine with a non-polar methyl-carbonyl group (−NHCOCH₃), and methylation (via COMT or TPMT) caps a polar phenolic −OH or thiol −SH with a hydrophobic methyl group (−OCH₃ or −SCH₃). The biological purpose of acetylation and methylation is electronic and steric inactivation: masking reactive aromatic amines prevents CYP1A2 oxidation into carcinogenic N-hydroxyarylamines, and O-methylating catecholamines terminates adrenergic receptor binding. Historically, early sulfonamide antibiotics with poorly soluble N⁴-acetyl metabolites precipitated as crystals inside acidic renal collecting ducts (crystalluria).

1. Williams, R. T. (1959). Detoxication Mechanisms: The Metabolism and Detoxication of Drugs, Toxic Substances and Other Organic Compounds (2nd ed.). Chapman & Hall. https://doi.org/10.1002/jps.3030490622
2. Guengerich, F. P. (2008). "Cytochrome P450 and Chemical Toxicology." Chemical Research in Toxicology, 21(1), 70–83. https://doi.org/10.1021/tx700079z
3. Kiang, T. K. L., Ensom, M. H. H., & Chang, T. K. H. (2005). "UDP-Glucuronosyltransferases and Clinical Drug–Drug Interactions." Pharmacology & Therapeutics, 106(1), 97–132. https://doi.org/10.1016/j.pharmthera.2004.10.013
4. Jancova, P., Anzenbacher, P., & Anzenbacherova, E. (2010). "Phase II Drug Metabolizing Enzymes." Biomedical Papers, 154(2), 103–116. https://doi.org/10.5507/bp.2010.017